Cambridge-based Enhanc3D Genomics has unveiled an integrated suite of multi-omics solutions designed to enhance drug discovery processes. The platform, which leverages proprietary Promoter Capture Hi-C technology, enables high-resolution mapping of genomewide regulatory interactions to support more targeted therapeutic development approaches.

The company’s core offering centres on patented technology that captures interactions between promoters and regulatory regions across the entire genome in a single assay. This approach allows researchers to analyse regulatory networks at unprecedented resolution, particularly valuable for understanding the role of non-coding regions in disease mechanisms.

Platform components and applications

The newly launched suite comprises several key components, each addressing specific challenges in the drug development pipeline. GenLinkConnect focuses on accelerating target identification by mapping relationships between GWAS-identified SNPs and their associated genes in specific cell types, with particular emphasis on long-range interactions that may be missed by conventional analysis methods. GenLinkResponse enables detailed analysis of cellular regulatory networks, specifically examining how cells respond to therapeutic compounds at the epigenetic level. This is complemented by GenLinkProfile, which integrates 3D genomics interaction data with multi-omics assays to generate high-resolution contact maps and context-aware analyses of SNP-gene interactions.

Data visualisation and integration

Supporting these analytical tools is GenLinkHub, a visualisation platform that transforms complex multi-omics datasets into interpretable 3D representations. The software overlays data onto high-resolution 3D genome maps and integrates both proprietary and curated public datasets to facilitate comprehensive analysis.

Dr Hazel Jones, CEO of Enhanc3D Genomics, said: “By harnessing the full potential of the non-coding genome our unique technology not only has the potential to accelerate the target discovery process, but can also be used to unveil new therapeutic possibilities. We have shown, through existing collaborations, that we can improve both timescales and success rates of target identification and drug development using 3D multi-omics.” The platform’s ability to generate cell-specific insights into gene regulation and disease mechanisms represents a significant advance in precision medicine approaches. According to CSO Dr Dan Turner, the company’s 3D MultiOmic Atlas provides comprehensive data for understanding regulatory mechanisms in specific cellular contexts, potentially streamlining the drug discovery process.

For more information, visit: enhanc3dgenomics.com/genlink-connect/
Digital issue: Please click here for more information

Dr Hazel Jones,
CEO of Enhanc3D
Genomics